SSY Group Expands Ophthalmic Product Line with New Approval

SSY Group ( (HK:2005) ) has shared an announcement.

SSY Group Limited has received approval from China’s National Medical Products Administration for the production and registration of Timolol Maleate Eye Drops in unit dose packaging. This marks the company’s first approval of this kind in China and is part of its strategy to expand its ophthalmic product line. The new product is designed to effectively reduce intraocular pressure in various types of glaucoma, enhancing SSY Group’s position in the pharmaceutical market and potentially opening new sales channels by the end of the year.

The most recent analyst rating on (HK:2005) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.

More about SSY Group

SSY Group Limited operates in the pharmaceutical industry, focusing on the development and production of ophthalmic preparation medicines. The company is expanding its market presence by introducing new drug formulations, particularly in the field of eye care.

YTD Price Performance: -15.48%

Average Trading Volume: 10,868,236

Technical Sentiment Signal: Sell

Current Market Cap: HK$8.62B

Find detailed analytics on 2005 stock on TipRanks’ Stock Analysis page.